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To investigate the relationship of cutaneous leishmani-
asis isolates from Sri Lanka to known species, we per-
formed DNA sequencing and microsatellite analyses. We
identified Leishmania donovani as the agent of Sri Lanka
cutaneous leishmaniasis and showed that these parasites
are closely related to those causing visceral leishmaniasis
in the Indian subcontinent.
Infection with Leishmania protozoa can result in cuta-neous, mucocutaneous, or visceral leishmaniasis (VL),
depending on the parasite, host, and environmental factors
(1). Globally, the disease results in ≈2 million new cases
and 2.4 million disability-adjusted life years each year (2).
The leishmaniases have received renewed interest because
of an upsurge of cases in traditionally leishmaniasis-
endemic areas and the emergence of new foci of disease
(3,4). One of the most dramatic examples is a new focus of
cutaneous leishmaniasis (CL) in Sri Lanka (5), from which
>400 cases have been reported since 2001.
Previously, multilocus enzyme electrophoresis
(MLEE) characterization of a small number of isolates led
to the surprising conclusion that CL in Sri Lanka was
caused by Leishmania donovani (5). However, L. donovani
typically causes VL, a potentially fatal disease and ongo-
ing public health problem in neighboring India,
Bangladesh, and Nepal, as well as in East Africa (1,2). No
cases of VL have been reported in Sri Lanka. Occasional
cases of CL due to L. donovani have been described in
other VL-endemic regions (6–9). Karunaweera et al. (5)
examined a limited number of isolates and used a single
technique, MLEE. Although this technique is usually reli-
able for characterizing isolates, important exceptions were
found in a recent study on L. donovani in East Africa (10).
Therefore, we further investigated Sri Lanka CL by exam-
ining more isolates and using 2 molecular techniques.
The Study
Suspected clinical diagnoses of CL were confirmed by
demonstrating the presence of Leishmania amastigotes in
skin lesions, promastigotes in cultures, or both (5). Ethical
approval was obtained from the Ethics Review Committee,
Faculty of Medicine, University of Colombo. PCR, per-
formed as described (11), confirmed 15 primary isolates as
members of the genus Leishmania. Eight of the Sri Lanka
isolates originated from Welioya (northeast), 1 from Jaffna
(north), and 2 from Galle (south).
DNA sequencing of a single-copy gene was used to
identify the Leishmania species (10). The 6-phosphoglu-
conate dehydrogenase (6PGDH) gene was chosen because
it shows a high degree of sequence polymorphism among
Leishmania species (12), is well represented in sequence
databases, and is known to differentiate the main
zymodeme from L. donovani in India (MON-2) from that
elsewhere (13). Primers for conserved regions of 6PGDH
were designed by using full-length gene sequences of the
L. major FV1 (MHOM/IL/1980/Friedlin) and L. mexicana
BEL21 (MHOM/BZ/1982/BEL21) reference strains.
Primers 6PGDH-F (AAT CGA GCA GCT CAA GGA AG)
and 6PGDH-R (GAG CTT GGC GAG AAT CTG AC)
were designed to generate a 997-bp amplicon incorporat-
ing the 822-nt partial 6PGDH sequence that is represented
for multiple Leishmania species in GenBank. The partial
sequences of 6PGDH genes were obtained from 11 Sri
Lanka isolates from patients with CL, 2 India isolates from
patients with VL, and 2 additional known L. donovani
strains. These 15 new sequences and 10 publicly available
sequences for species belonging to the genus Leishmania
were used to construct a classification (Figure 1). Of 17 L.
donovani and L. infantum sequences, 14 were >99% iden-
tical and could not be separated; the remaining 3 stocks
were from India and Bangladesh (Ind-1, Ind-2, and BG1)
and clustered together with 58% bootstrap support. Thus,
L. donovani from Sri Lanka formed a strongly supported
group with L. donovani and L. infantum from Europe and
Africa. This group was quite distinct from the group that
includes L. major and L. tropica, which are the parasite
species most closely related to L. donovani and L. infantum
and which both cause CL in Africa and Asia. This analysis
provided convincing evidence that all 11 Sri Lanka isolates
examined were L. donovani or L. infantum.
Strains of L. donovani from Sri Lanka were typed as
zymodeme MON-37 by MLEE (5). This differs from the
predominant India zymodeme (MON-2) in the mobility of
1 isoenzyme, 6PGDH. Therefore, the sequences were fur-
ther analyzed to investigate the sequence variation under-
lying the isoenzyme identification. Translation of the
822-nt sequences showed 1 amino acid change that was
consistent with the results of MLEE. A single nucleotide
difference at position 976 was responsible for the occur-
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rence of an uncharged asparagine (codon AAC) in MON-
2 or a negatively charged aspartic acid (codon GAC) in
MON-1, MON-18, and MON-37 sequences. This single
change would explain the lower mobility of the MON-2
6PGDH isoenzyme, similar to the situation previously
reported for glutamate oxaloacetate transaminase isoen-
zymes in East Africa L. donovani strains (10).
To more closely analyze the relationships of the L.
donovani and L. infantum strains, we performed
microsatellite analysis (10). These data were combined
with a dataset comprising 40 previously examined L.
donovani and L. infantum isolates (Figure 2). The Sri
Lanka isolates clustered together and close to a group con-
taining L. donovani isolates from India, Bangladesh, and
Nepal. L. infantum isolates formed a distinct cluster, as did
the L. donovani isolates from Sudan and Kenya. This
analysis reconfirms recent observations (10,14) that L.
donovani isolates tend to cluster on a geographic basis,
which suggests that strains of this parasite are geographi-
cally distinct. Also, although the Sri Lanka isolates form 1
or possibly 2 distinct groups, they are most closely related
to L. donovani, which causes VL in India, and distant from
L. infantum parasites.
Conclusions
The results of this study led us to conclude that in Sri
Lanka, CL is caused by L. donovani, which affects the epi-
demiology and clinical management of leishmaniasis. CL
in Sri Lanka can no longer be regarded as a minor prob-
lem; an explosion of cases in the past 5 years, undoubted-
ly an underrepresentation of the true incidence of disease,
has not included a single case of VL. However, the possi-
bility that VL will emerge should be considered because
subclinical infection is frequent in VL-endemic areas (15).
The clinical management of CL is often self-cure, which
may be preferable to active treatment because self-cure
may promote natural immunity to reinfection.
Alternatively, antileishmanial drugs may be administered
topically or by intralesional injection (2). However, L.
donovani is recognized as one of the great scourges of
mankind (3,4), and if visceral disease does emerge as a
problem, more aggressive treatment of CL in Sri Lanka
should be considered, e.g., parenteral administration of
antimonial compounds, amphotericin, or oral miltefosine.
Unfortunately, no drugs are currently registered for the
treatment of leishmaniasis in Sri Lanka, and cryotherapy is
the only available option in most healthcare centers. Better
availability of drugs to treat CL in Sri Lanka is needed, but
their introduction must be carefully monitored and critical-
ly evaluated.
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Figure 1. Classification of Leishmania species according to the
partial DNA sequence of the 6-phosphogluconate dehydrogenase
gene constructed with PHYLIP (http://evolution.genetics.
washington.edu/phylip.html) using parsimony. Numbers at branch
points are bootstrap values compiled by using 100 replicates.
Isolates examined and the accession numbers of their 6PGDH
sequences in the GenBank/EMBL/DDBJ database are as follows:
11 Sri Lanka isolates, L59, L60, L75, L78, L80, L284, L304, L355,
L330, L301, L348 (AJ888888-AJ888898); 2 India isolates, Ind-1,
Ind-2 from splenic aspirates of visceral leishmaniasis patients in
Muzafapur, Bihar (MHOM/IN/2004/Ind-1 and MHOM/IN/2004/Ind-
2, AJ888900, AJ888901); 3 previously identified L. donovani iso-
lates BG1 (MHOM/BD/1997/BG1, AJ888899), LEM719
(IMAR/KE/1962/LRC-L57; LEM719, AJ888902), LV9
(MHOM/ET/1967/HU3;LV9, AY168567); and L. infantum JPC
(MCAN/ES/1998/LEM935;JPC;M5, GeneDB LinJ35.2940). Also
analyzed were sequences from the following isolates: L. tropica
(AY045763, AY168568), L. major (FV1, AF242436; 8A1,
AF242436; RTC13, AY706106; JerII, AY706105; 5ASKH,
AY706107), L. mexicana (M379, AY217723; BEL21, AY386372),
and L. amazonensis (PH8, AY168562).
Figure 2. Classification of Leishmania donovani and L. infantum
isolates constructed by using microsatellite data with parsimony in
PAUP (Sinauer Associates Inc., Sunderland, MA, USA). Numbers
at branch points are bootstrap values compiled by using 100 repli-
cates. Isolates formed geographically based groups (circled). Sri
Lanka isolates L59, L60, L75, L78, and L80 are indicated. The tips
of other branches are from a dataset of other previously analyzed
isolates, including all those identified as L. donovani or L. infantum
and isolates from the Indian subcontinent (10).
Our study also raises questions about how infection
with apparently identical or very similar parasites can
result in radically different types of disease. We speculate
that the answers likely lie with the nature of the parasites,
the genetics of the human population, or the contribution
of sandfly vectors. The data presented here demonstrate
the overall close genetic similarity among all L. donovani
isolates examined. However, some critical genetic differ-
ence in Sri Lanka parasites may exist and render them less
virulent than L. donovani from elsewhere. Clearly much
work remains to be done, including PCR or serologic
investigation of possible subclinical VL, to understand the
factors behind the emergence of Sri Lanka CL due to L.
donovani. Future studies must be a priority as the number
of cases continues to increase.
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